患者由来異種移植片/PDXモデル市場：タイプ、腫瘍タイプ、用途、エンドユーザー別-2024-2030年の世界予測

患者由来異種移植片/PDXモデル市場規模は、2023年に2億2,226万米ドルと推定され、2024年には2億5,351万米ドルに達し、CAGR 14.54%で2030年には5億7,499万米ドルに達すると予測されています。

患者由来異種移植（PDX）モデルとは、ヒト腫瘍組織や細胞を免疫不全マウスやヒト化マウスに直接移植し、生体内で患者の腫瘍を増殖・維持できるようにした最先端のがん研究・医薬品開発ツールです。世界のがん罹患率の増加により、効果的な治療法に対する需要が高まり、研究開発活動への投資が増加しています。しかし、患者組織サンプルの入手に伴う倫理的・規制的懸念や、ヒトとマウスの生理学的相違が、患者由来異種移植（PDX）モードの成長を抑制しています。さらに、がん研究に対する政府の資金援助の増加や分子特性解析技術の進歩は、将来的に有利な機会を生み出すと予想されます。

タイプ新規治療薬を開発するために腫瘍学でマウスモデルが広く使用されている

マウスモデルは、小型で取り扱いが容易であり、ヒトと遺伝的に類似しているなどの特性から、最も広く使用されているPDXモデルです。これらのモデルは腫瘍生物学の理解や腫瘍学における新規治療法の開発に大きく貢献しています。一方、ラットモデルはサイズが大きく、外科手術、画像診断、サンプリングに有利であるため、マウスPDXモデルに代わる貴重なモデルとして登場しました。さらに、ラットは神経膠腫や肉腫など特定のヒトがん種のモデル化において、より多様な免疫応答と高い忠実性を示します。

腫瘍の種類：婦人科がんを研究するための婦人科腫瘍モデルに重点を置く。

消化器（GI）腫瘍モデルは、大腸がん、胃がん、膵がんなど消化器系に影響を及ぼすがんを研究する上で極めて重要です。これらのモデルは、腫瘍の発生や転移の根本的なメカニズムを調べ、潜在的な治療法を評価するのに役立ちます。婦人科腫瘍モデルは、卵巣がん、子宮内膜がん、子宮頸がんを含む婦人科がんの研究に不可欠です。血液腫瘍モデルは、白血病、リンパ腫、多発性骨髄腫などの血液がんの研究に用いられます。呼吸器腫瘍モデルは、肺がんの病態や治療法の研究に不可欠です。泌尿器腫瘍モデルは、膀胱がん、腎臓がん、前立腺がんなどの泌尿器系のがんを研究するのに重要であり、研究者が疾患の発生を理解し、個別化された治療戦略を同定するのに役立ちます。

応用：基礎がん研究への患者由来異種移植（PDX）モデルの採用増加

患者由来異種移植片（PDX）モデルは、腫瘍環境や患者の不均一性を忠実に模倣するため、基礎的ながん研究において非常に価値が高いです。バイオマーカー解析は、個々の患者の治療決定を導く予測マーカーや予後マーカーを同定するために不可欠です。PDXモデルは、腫瘍の成長と治療反応における分子変化を捉えることにより、包括的なバイオマーカー開発を可能にします。前臨床医薬品開発は、治験薬の安全性、有効性、薬物動態学的特性を評価するためにPDXモデルに大きく依存しています。PDXモデルはヒトのがんの複雑さと多様性を再現するため、臨床試験に入る前に抗がん剤を評価するための好ましい選択肢です。

エンドユーザー：学術・研究機関における患者由来異種移植片の応用可能性の高まり

学術・研究機関は主に、がん生物学、薬効試験、個別化医療開発の研究を促進しています。これらの機関では、新規治療標的の同定や腫瘍進行メカニズムの理解のためにPDXモデルを使用しています。開発業務受託機関（CRO）は、創薬や研究開発のためにPDXモデルを用いて、製薬企業やバイオテクノロジー企業に前臨床試験や臨床試験のサービスを提供しています。CROは、ターゲット同定／バリデーション、リード最適化、薬物動態／薬力学（PK/PD）試験、毒性評価など、医薬品開発のさまざまな段階でこれらのモデルを適用しています。製薬企業やバイオテクノロジー企業は、創薬パイプラインをサポートし、個別化されたがん治療に対する需要に対応するためにPDXモデルを採用しています。

地域別インサイト

南北アメリカのPDX市場は、政府の支援策やこの分野の進歩に貢献する様々な研究機関の存在により、非常に発展しています。さらに、この地域のバイオテクノロジー企業は、創薬や個別化医療アプローチのためのPDXサービスを提供することに大きな意義があります。欧州連合（EU）では、EUが資金提供するプロジェクトが、加盟国全体でPDXモデルへのアクセスを拡大することに重点を置いています。中東ではPDXモデル研究への関心が高まっており、前臨床がんモデル開発のための専門知識やリソースを育成する組織がイニシアチブをとっています。アジア太平洋地域では、生物医学研究への投資により、国内製薬企業によるPDXモデル研究が急増しています。アジア太平洋地域の政府の枠組みもPDXモデル研究を促進するイニシアチブを支援しており、患者由来異種移植片/PDXモデル市場の潜在的なプラットフォームを開発しています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは患者由来異種移植片/PDXモデル市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、患者由来異種移植片/PDXモデル市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.患者由来異種移植片/PDXモデル市場の市場規模および予測は？

2.患者由来異種移植片/PDXモデル市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.患者由来異種移植片/PDXモデル市場の技術動向と規制枠組みは？

4.患者由来異種移植片/PDXモデル市場における主要ベンダーの市場シェアは？

5.患者由来異種移植片/PDXモデル市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 個別化医療の需要の高まり
    • 腫瘍学および前臨床開発
    • 申請者が前臨床プログラムと文書を準備するための政府プログラムの資金とサービス
  • 抑制要因
    • パーソナライズされたPDXモデルの高コスト
  • 機会
    • 人間化されたPDXモデルの需要の高まり
    • 医薬品研究開発の成長
  • 課題
    • がん調査における動物の倫理的使用に関する厳格なガイドライン
• 市場セグメンテーション分析
  • タイプ：腫瘍学におけるマウスモデルの広範な使用による新規治療法の開発
  • 腫瘍の種類：婦人科がんを研究するための婦人科腫瘍モデルに重点を置く
  • 応用：基礎がん調査における患者由来異種移植（PDX）モデルの採用拡大
  • エンドユーザー：学術調査機関における患者由来異種移植の適用範囲の拡大
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 患者由来異種移植片/PDXモデル市場：タイプ別

• マウスモデル
• ラットモデル

第7章 患者由来異種移植片/PDXモデル市場腫瘍の種類別

• 消化管腫瘍モデル
• 婦人科腫瘍モデル
• 血液腫瘍モデル
• 呼吸器腫瘍モデル
• 泌尿器腫瘍モデル

第8章 患者由来異種移植片/PDXモデル市場：用途別

• がんの基礎調査
• バイオマーカー分析
• 前臨床医薬品開発

第9章 患者由来異種移植片/PDXモデル市場：エンドユーザー別

• 学術・調査機関
• 契約調査機関
• 製薬・バイオテクノロジー企業

第10章 南北アメリカの患者由来異種移植片/PDXモデル市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の患者由来異種移植片/PDXモデル市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの患者由来異種移植片/PDXモデル市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • KiyatecとXenostartは、Kiyatecの3DスフェロイドスクリーニングプラットフォームであるKiya-Predictを使用して相関的な体外有効性データを提供し、医薬品開発コストの削減を支援するための協力契約を正式に発表しました。
  • SoteriaとCertisがAIプラットフォームとマウス異種移植を使用して薬剤反応予測を生成するために提携
  • ジェムファーマテックとチャールズリバーラボラトリーズが次世代NCGポートフォリオの販売に関する独占契約を締結
• 戦略分析と提言

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
• FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
• FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 51. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 52. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 53. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 54. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 57. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 58. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 59. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 60. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 61. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 62. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 63. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 66. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 67. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 68. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 69. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 70. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 71. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 72. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 73. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 74. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 75. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 76. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 77. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 78. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 79. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 80. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 81. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 82. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 83. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 84. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 85. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 86. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 87. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 90. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 91. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 92. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 94. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 96. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 102. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 103. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 104. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 105. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 106. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 107. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 108. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 109. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 110. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 111. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 112. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 113. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 114. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 115. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 120. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 121. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 122. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 123. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 126. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 127. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 128. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 129. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 130. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 131. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 132. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 133. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 134. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 135. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 136. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 137. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 138. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 139. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 144. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 145. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 146. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 147. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 148. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 149. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 150. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 151. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 152. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 153. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 154. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 155. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 156. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 157. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 158. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 159. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 160. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 161. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 162. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 163. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 168. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 170. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 174. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 175. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 176. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 177. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 178. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 179. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 180. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 181. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 182. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 183. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 184. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 185. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 186. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 187. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 190. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 191. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 192. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 193. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 194. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 195. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 198. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 209. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 210. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 211. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 212. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 213. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 216. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 217. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 218. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 219. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 220. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 221. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 222. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 223. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 224. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 225. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 226. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 227. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 228. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 229. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 230. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 231. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 232. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 233. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 234. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 235. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 236. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 237. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 240. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 241. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 242. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 243. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 244. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 245. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 246. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 247. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 248. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 249. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 250. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 251. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 252. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 253. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 254. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 255. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 256. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 257. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 258. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 259. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 260. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 261. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 264. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 265. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 266. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 267. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 268. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 269. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 270. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 271. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 272. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 273. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 274. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 275. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 276. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 277. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 278. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 279. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 280. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 281. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 282. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 283. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 284. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 285. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 288. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 289. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 290. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 291. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 292. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 293. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 294. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 295. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 296. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 297. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 298. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 299. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
• TABLE 300. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
• TABLE 301. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 302. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 303. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 304. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024

[197 Pages Report] The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 222.26 million in 2023 and expected to reach USD 253.51 million in 2024, at a CAGR 14.54% to reach USD 574.99 million by 2030.

A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.

Type: Extensive use of mouse models in oncology to develop novel therapeutics

Mice models are the most widely used PDX models due to their properties such as small size, ease of handling, and genetic similarity to humans. These models contribute significantly to understanding tumor biology and developing novel therapeutic approaches in oncology. On the other hand, rat models have emerged as a valuable alternative to mice PDX models due to their larger size, which benefits surgical procedures, imaging, and sampling. Additionally, rats exhibit more diverse immune responses and higher fidelity in modeling certain human cancer types, such as glioma and sarcoma.

Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers

Gastrointestinal (GI) tumor models are crucial to studying cancers that affect the digestive system, such as colorectal, gastric, and pancreatic cancer. These models aid in examining the underlying mechanisms of tumor development and metastasis and evaluating potential therapeutic options. Gynecological tumor models are essential for studying gynecological cancers, including ovarian, endometrial, and cervical cancer. Researchers employ hematological tumor models to study blood cancers, including leukemia, lymphoma, and multiple myeloma. Respiratory tumor models are vital for investigating lung cancer pathogenesis and treatment options. Urological tumor models, crucial for studying cancers of the urinary system such as bladder, kidney, and prostate cancer, aid researchers in comprehending disease development and identifying personalized treatment strategies.

Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research

Patient-derived xenograft (PDX) models are highly valuable in basic cancer research as they closely mimic the tumor environment and patient heterogeneity. Biomarker analysis is essential for identifying predictive or prognostic markers that guide treatment decisions for individual patients. PDX models enable comprehensive biomarker development by capturing molecular changes during tumor growth and therapy response. Preclinical drug development relies heavily on PDX models to assess investigational therapies' safety, efficacy, and pharmacokinetic properties. They are a preferred choice for evaluating anticancer agents before entering clinical trials, as PDX models replicate the complexity and diversity of human cancers.

End-User: Rising applicability of patient-derived xenografts in academic and research institutes

Academic and research institutions primarily facilitate the study of cancer biology, drug efficacy testing, and personalized medicine development. These institutions use PDX models to identify novel therapeutic targets and understand tumor progression mechanisms. Contract Research Organizations (CROs) offer preclinical and clinical trial services for pharmaceutical and biotechnology companies using PDX models for drug discovery and development. CROs apply these models in various stages of drug development, including target identification/validation, lead optimization, pharmacokinetics/pharmacodynamics (PK/PD) studies, and toxicity evaluation. Pharmaceutical and biotechnology companies employ PDX models to support their drug discovery pipelines and address the demand for personalized oncology treatments.

Regional Insights

The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region's investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Patient-Derived Xenograft/PDX Model Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Mice Models
  • Rat Models

• Tumor Type
  • Gastrointestinal Tumor Models
  • Gynecological Tumor Models
  • Hematological Tumor Models
  • Respiratory Tumor Models
  • Urological Tumor Models

• Application
  • Basic Cancer Research
  • Biomarker Analysis
  • Preclinical Drug Development

• End-User
  • Academic & Research Institutions
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Patient-Derived Xenograft/PDX Model Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Patient-Derived Xenograft/PDX Model Market?

3. What are the technology trends and regulatory frameworks in the Patient-Derived Xenograft/PDX Model Market?

4. What is the market share of the leading vendors in the Patient-Derived Xenograft/PDX Model Market?

5. Which modes and strategic moves are suitable for entering the Patient-Derived Xenograft/PDX Model Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for personalized medicine
    • 5.1.1.2. Oncology and preclinical development
    • 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of personalized PDX model
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising demand for humanized PDX Model
    • 5.1.3.2. Growth in pharma R&D
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
  • 5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
  • 5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
  • 5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Patient-Derived Xenograft/PDX Model Market, by Type

• 6.1. Introduction
• 6.2. Mice Models
• 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

• 7.1. Introduction
• 7.2. Gastrointestinal Tumor Models
• 7.3. Gynecological Tumor Models
• 7.4. Hematological Tumor Models
• 7.5. Respiratory Tumor Models
• 7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

• 8.1. Introduction
• 8.2. Basic Cancer Research
• 8.3. Biomarker Analysis
• 8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

• 9.1. Introduction
• 9.2. Academic & Research Institutions
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec's 3D Spheroid Screening Platform, Kiya-Predict
  • 13.3.2. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
  • 13.3.3. GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio